Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 2136-2140

  Lord, R ^a,b,c,d   Nair, S ^a   Schache, A ^b   Spicer, J ^a,b,c,d   Somaihah, Navita ^a,b,c,d   Khoo, V ^c   Pandha, H ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b FRIMLEY PARK HOSPITAL   (United Kingdom)

^c Royal Marsden Hospital   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

cyclophosphamide; prostatic neoplasms

Indexed keywords

CYCLOPHOSPHAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GENE TARGETING; HUMAN; IMMUNITY; KIDNEY DISEASE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34248190133     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.143     Document Type: Article

References (16)

1. Zhang Y., Glass A., Bennett N., Oyama K.A., Gehan E., and Gelmann E.P. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer 100 (2004) 300
2. Albini A., Tosetti F., Benelli R., and Noonan D.M. Tumour inflammatory angiogenesis and its chemoprevention. Cancer Res 65 (2005) 10637
3. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., and Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105 (2005) 2862
4. Damber J.E., Vallbo C., Albertsson P., Lennernas B., and Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 158 (2005) 354
5. Hanahan D., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045
6. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878
7. Man S., Bocci G., Francia G., Green S.K., Jothy S., Hanahan D., et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62 (2002) 2731
8. Gehan E.A. Clinical trials in cancer research. Environ Health Perspect 32 (1979) 31
9. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42
10. Schellhammer P.F., and Hershberg R.M. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 23 (2005) 47
11. Michael A., Ball G., Quatan N., Wushishi F., Russell N., Whelan J., et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11 (2005) 4469
12. Chlebowski R.T., Hestorff R., Sardoff L., Weiner J., and Bateman J.R. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. Cancer 42 (1978) 2546
13. Nicolini A., Mancini P., Ferrari P., Anselmi L., Tartarelli G., Bonazzi V., et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 58 (2004) 447
14. Albertsson P., Lennernas B., and Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS 111 (2003) 995
15. Nicholson B., and Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91 (2004) 125
16. Hamano Y., Sugimoto H., Soubasakos M.A., Kieran M., Olsen B.R., Lawler J., et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64 (2004) 1570